# A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer

> **NCT02151084** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 57 (actual)

## Conditions studied

- Biliary Tract Carcinoma
- Gallbladder Carcinoma

## Interventions

- **DRUG:** Selumetinib
- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02151084
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-11
- **Primary completion:** 2026-05
- **Final completion:** 2026-09
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02151084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02151084, "A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02151084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*